Department of Gastroenterology, Beijing Digestive Disease Center, Beijing Friendship Hospital affiliated to Capital Medical University, Yong'an Road 95, Beijing, China.
Cancer Lett. 2011 Oct 1;309(1):19-26. doi: 10.1016/j.canlet.2011.05.010. Epub 2011 Jun 8.
COX-2 and 5-LOX are up-regulated in ESCC. This study aims to determine the efficacy of COX-2 inhibitor, 5-LOX inhibitor and their combination on ESCC. Nimesulide can suppress cell growth and promote apoptosis, accompanied with a decrease of PGE(2) production. AA861 has the similar effect with a down-regulation of LTB(4). In animal experiment, the tumor volumes in drug-treated groups were significantly smaller with the lowest rates of Ki-67 positive cells. In conclusion, either COX-2 inhibitor or 5-LOX inhibitor can suppress ESCC. Dual inhibition of COX-2 and 5-LOX pathway may present a superior anticancer efficacy to either inhibition of COX-2 or 5-LOX alone.
COX-2 和 5-LOX 在 ESCC 中上调。本研究旨在确定 COX-2 抑制剂、5-LOX 抑制剂及其联合应用对 ESCC 的疗效。尼美舒利可以抑制细胞生长，促进细胞凋亡，同时降低 PGE（2）的产生。AA861 具有相似的作用，下调 LTB（4）。在动物实验中，药物治疗组的肿瘤体积明显较小，Ki-67 阳性细胞的比例最低。总之，COX-2 抑制剂或 5-LOX 抑制剂均可抑制 ESCC。COX-2 和 5-LOX 通路的双重抑制可能比单独抑制 COX-2 或 5-LOX 具有更好的抗癌疗效。
